UB Paderborn / Katalog / Suche / in CDI

Prescription Drug Monitoring Program Mandates: Impact On Opioid Prescribing And Related Hospital Use

Health affairs (Millwood, Va.), 2019-09, Vol.38 (9), p.1550-1556S

2019

Volltextzugriff (PDF)

Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration

Addiction science & clinical practice, 2023-05, Vol.18 (1), p.34-34, Article 34

2023

Volltextzugriff (PDF)

Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials

Addiction science & clinical practice, 2020-04, Vol.15 (1), p.15-15, Article 15

2020

Volltextzugriff (PDF)

The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City

Drug and alcohol dependence reports, 2022-09, Vol.4, p.100083, Article 100083

2022

Volltextzugriff (PDF)

Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions

Health affairs (Millwood, Va.), 2018-10, Vol.37 (10), p.1596-9

2018

Volltextzugriff (PDF)

State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals

Clinical infectious diseases, 2018-05, Vol.66 (10), p.1618-1620

2018

Volltextzugriff (PDF)

Association between jail‐based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011–17

Addiction (Abingdon, England), 2023-03, Vol.118 (3), p.459-467

2023

Volltextzugriff (PDF)

State Policies for Prescription Drug Monitoring Programs and Adverse Opioid-related Hospital Events

Medical care, 2020-07, Vol.58 (7), p.610

2020

Volltextzugriff (PDF)

Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse

Annals of internal medicine, 2019-01, Vol.170 (2), p.90

2019

Volltextzugriff (PDF)

Will converting naloxone to over‐the‐counter status increase pharmacy sales?

Health services research, 2019-08, Vol.54 (4), p.764-772

2019

Volltextzugriff (PDF)

Robust Prescription Monitoring Programs and Abrupt Discontinuation of Long-term Opioid Use

American journal of preventive medicine, 2021-10, Vol.61 (4), p.537-544

2021

Volltextzugriff (PDF)

Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration

Drug and alcohol dependence, 2024-06, Vol.259, p.111274, Article 111274

2024

Volltextzugriff (PDF)

Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study

Drug and alcohol dependence, 2024-08, Vol.261, p.111377, Article 111377

2024

Volltextzugriff (PDF)

The Learning Curve After Implementation of Collaborative Care in a State Mental Health Integration Program

Psychiatric services (Washington, D.C.), 2019-02, Vol.70 (2), p.139-142

2019

Volltextzugriff (PDF)

State Opioid Limits and Volume of Opioid Prescriptions Received by Medicaid Patients

Medical care, 2020-12, Vol.58 (12), p.1111

2020

Volltextzugriff (PDF)

First Opioid Prescription and Subsequent High-Risk Opioid Use: a National Study of Privately Insured and Medicare Advantage Adults

Journal of general internal medicine : JGIM, 2018-12, Vol.33 (12), p.2156-2162

2018

Volltextzugriff (PDF)

Comparison of a national commercial pharmacy naloxone data source to state and city pharmacy naloxone data sources-Rhode Island, Massachusetts, and New York City, 2013-2019

Health services research, 2023-10, Vol.58 (5), p.1141-1150

2023

Volltextzugriff (PDF)

Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial

Drug and alcohol dependence, 2020-10, Vol.215, p.108221-108221, Article 108221

2020

Volltextzugriff (PDF)

Cost‐effectiveness implications of increasing the efficiency of the extended‐release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis

Addiction (Abingdon, England), 2021-12, Vol.116 (12), p.3444-3453

2021

Volltextzugriff (PDF)

Cost of an HIV Medical Care Coordination Program in Los Angeles County

Journal of acquired immune deficiency syndromes (1999), 2019-05, Vol.81 (1), p.e15

2019

Volltextzugriff (PDF)

Diagnostic Coding of Elder Mistreatment: Results From a National Database of Medicare Advantage and Private Insurance Patients, 2011–2017

Journal of applied gerontology, 2022-04, Vol.41 (4), p.918-927

2022

Volltextzugriff (PDF)

Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis

Journal of substance use and addiction treatment, 2024-03, Vol.158, p.209254-209254, Article 209254

2024

Volltextzugriff (PDF)

Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities

Journal of substance use and addiction treatment, 2023-03, Vol.146, p.208943-208943, Article 208943

2023

Volltextzugriff (PDF)

Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County

Open forum infectious diseases, 2019-12, Vol.6 (12), p.ofz537-ofz537

2019

Volltextzugriff (PDF)

Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release

Journal of substance abuse treatment, 2022-10, Vol.141, p.108835-108835, Article 108835

2022

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Prescription Drug Monitoring Program Mandates: Impact On Opioid Prescribing And Related Hospital Use

Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration

Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials

The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City

Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions

State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals

Association between jail‐based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011–17

State Policies for Prescription Drug Monitoring Programs and Adverse Opioid-related Hospital Events

Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse

Will converting naloxone to over‐the‐counter status increase pharmacy sales?

Robust Prescription Monitoring Programs and Abrupt Discontinuation of Long-term Opioid Use

Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration

Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study

The Learning Curve After Implementation of Collaborative Care in a State Mental Health Integration Program

State Opioid Limits and Volume of Opioid Prescriptions Received by Medicaid Patients

First Opioid Prescription and Subsequent High-Risk Opioid Use: a National Study of Privately Insured and Medicare Advantage Adults

Comparison of a national commercial pharmacy naloxone data source to state and city pharmacy naloxone data sources-Rhode Island, Massachusetts, and New York City, 2013-2019

Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial

Cost‐effectiveness implications of increasing the efficiency of the extended‐release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis

Cost of an HIV Medical Care Coordination Program in Los Angeles County

Diagnostic Coding of Elder Mistreatment: Results From a National Database of Medicare Advantage and Private Insurance Patients, 2011–2017

Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis

Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities

Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County

Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release

Suchergebnisse filtern